Last reviewed · How we verify

Nifedipine GITS (Adalat® XL 30

Shanghai Jiao Tong University School of Medicine · FDA-approved active Small molecule

Nifedipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure.

Nifedipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure. Used for Hypertension, Angina pectoris.

At a glance

Generic nameNifedipine GITS (Adalat® XL 30
SponsorShanghai Jiao Tong University School of Medicine
Drug classCalcium channel blocker (dihydropyridine)
TargetL-type calcium channel
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Nifedipine selectively blocks L-type calcium channels in the cell membrane, preventing calcium-dependent contraction of vascular smooth muscle. This leads to peripheral vasodilation, reduced systemic vascular resistance, and decreased blood pressure. The GITS (Gastrointestinal Therapeutic System) formulation provides extended-release delivery over 24 hours for once-daily dosing.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: